Flora Cimmino1, Vito Alessandro Lasorsa1,2, Simona Vetrella3, Achille Iolascon1,2, Mario Capasso1,2. 1. CEINGE Biotecnologie Avanzate, Napoli, Italy. 2. Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Napoli, Italy. 3. Department of Pediatric Oncology, Santobono-Pausilipon Children's Hospital, Naples, Italy.
Abstract
BACKGROUND: Liquid biopsies do not reflect the complete mutation profile of the tumor but have the potential to identify actionable mutations when tumor biopsies are not available as well as variants with low allele frequency. Most retrospective studies conducted in small cohorts of pediatric cancers have illustrated that the technology yield substantial potential in neuroblastoma. AIM: The molecular landscape of neuroblastoma harbors potentially actionable genomic alterations. We aimed to study the utility of liquid biopsy to characterize the mutational landscape of primary neuroblastoma using a custom gene panel for ctDNA targeted sequencing. METHODS: Targeted next-generation sequencing (NGS) was performed on ctDNA of 11 patients with primary neuroblastoma stage 4. To avoid the detection of false variants, we used UMIs (unique molecular identifiers) for the library construction, increased the sequencing depth and developed ad hoc bioinformatic analyses including the hard filtering of the variant calls. RESULTS: We identified 9/11 (81.8%) patients who carry at least one pathogenic variation. The most frequently mutated genes were KMT2C (five cases), NOTCH1/2 (four cases), CREBBP (three cases), ARID1A/B (three cases), ALK (two cases), FGFR1 (two cases), FAT4 (two cases) and CARD11 (two cases). CONCLUSIONS: We developed a targeted NGS approach to identify tumor-specific alterations in ctDNA of neuroblastoma patients. Our results show the reliability of our approach to generate genomic information which can be integrated with clinical and pathological data at diagnosis.
BACKGROUND: Liquid biopsies do not reflect the complete mutation profile of the tumor but have the potential to identify actionable mutations when tumor biopsies are not available as well as variants with low allele frequency. Most retrospective studies conducted in small cohorts of pediatric cancers have illustrated that the technology yield substantial potential in neuroblastoma. AIM: The molecular landscape of neuroblastoma harbors potentially actionable genomic alterations. We aimed to study the utility of liquid biopsy to characterize the mutational landscape of primary neuroblastoma using a custom gene panel for ctDNA targeted sequencing. METHODS: Targeted next-generation sequencing (NGS) was performed on ctDNA of 11 patients with primary neuroblastoma stage 4. To avoid the detection of false variants, we used UMIs (unique molecular identifiers) for the library construction, increased the sequencing depth and developed ad hoc bioinformatic analyses including the hard filtering of the variant calls. RESULTS: We identified 9/11 (81.8%) patients who carry at least one pathogenic variation. The most frequently mutated genes were KMT2C (five cases), NOTCH1/2 (four cases), CREBBP (three cases), ARID1A/B (three cases), ALK (two cases), FGFR1 (two cases), FAT4 (two cases) and CARD11 (two cases). CONCLUSIONS: We developed a targeted NGS approach to identify tumor-specific alterations in ctDNA of neuroblastoma patients. Our results show the reliability of our approach to generate genomic information which can be integrated with clinical and pathological data at diagnosis.
Authors: Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956
Authors: Oliver A Zill; Kimberly C Banks; Stephen R Fairclough; Stefanie A Mortimer; James V Vowles; Reza Mokhtari; David R Gandara; Philip C Mack; Justin I Odegaard; Rebecca J Nagy; Arthur M Baca; Helmy Eltoukhy; Darya I Chudova; Richard B Lanman; AmirAli Talasaz Journal: Clin Cancer Res Date: 2018-05-18 Impact factor: 12.531
Authors: Susanne N Gröbner; Barbara C Worst; Joachim Weischenfeldt; Ivo Buchhalter; Kortine Kleinheinz; Vasilisa A Rudneva; Pascal D Johann; Gnana Prakash Balasubramanian; Maia Segura-Wang; Sebastian Brabetz; Sebastian Bender; Barbara Hutter; Dominik Sturm; Elke Pfaff; Daniel Hübschmann; Gideon Zipprich; Michael Heinold; Jürgen Eils; Christian Lawerenz; Serap Erkek; Sander Lambo; Sebastian Waszak; Claudia Blattmann; Arndt Borkhardt; Michaela Kuhlen; Angelika Eggert; Simone Fulda; Manfred Gessler; Jenny Wegert; Roland Kappler; Daniel Baumhoer; Stefan Burdach; Renate Kirschner-Schwabe; Udo Kontny; Andreas E Kulozik; Dietmar Lohmann; Simone Hettmer; Cornelia Eckert; Stefan Bielack; Michaela Nathrath; Charlotte Niemeyer; Günther H Richter; Johannes Schulte; Reiner Siebert; Frank Westermann; Jan J Molenaar; Gilles Vassal; Hendrik Witt; Birgit Burkhardt; Christian P Kratz; Olaf Witt; Cornelis M van Tilburg; Christof M Kramm; Gudrun Fleischhack; Uta Dirksen; Stefan Rutkowski; Michael Frühwald; Katja von Hoff; Stephan Wolf; Thomas Klingebiel; Ewa Koscielniak; Pablo Landgraf; Jan Koster; Adam C Resnick; Jinghui Zhang; Yanling Liu; Xin Zhou; Angela J Waanders; Danny A Zwijnenburg; Pichai Raman; Benedikt Brors; Ursula D Weber; Paul A Northcott; Kristian W Pajtler; Marcel Kool; Rosario M Piro; Jan O Korbel; Matthias Schlesner; Roland Eils; David T W Jones; Peter Lichter; Lukas Chavez; Marc Zapatka; Stefan M Pfister Journal: Nature Date: 2018-02-28 Impact factor: 49.962
Authors: Jeanne Tie; Yuxuan Wang; Cristian Tomasetti; Lu Li; Simeon Springer; Isaac Kinde; Natalie Silliman; Mark Tacey; Hui-Li Wong; Michael Christie; Suzanne Kosmider; Iain Skinner; Rachel Wong; Malcolm Steel; Ben Tran; Jayesh Desai; Ian Jones; Andrew Haydon; Theresa Hayes; Tim J Price; Robert L Strausberg; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs Journal: Sci Transl Med Date: 2016-07-06 Impact factor: 17.956
Authors: Benjamin G Bitler; Katherine M Aird; Azat Garipov; Hua Li; Michael Amatangelo; Andrew V Kossenkov; David C Schultz; Qin Liu; Ie-Ming Shih; Jose R Conejo-Garcia; David W Speicher; Rugang Zhang Journal: Nat Med Date: 2015-02-16 Impact factor: 53.440
Authors: Olivia M Padovan-Merhar; Pichai Raman; Irina Ostrovnaya; Karthik Kalletla; Kaitlyn R Rubnitz; Eric M Sanford; Siraj M Ali; Vincent A Miller; Yael P Mossé; Meaghan P Granger; Brian Weiss; John M Maris; Shakeel Modak Journal: PLoS Genet Date: 2016-12-20 Impact factor: 5.917
Authors: Francesco Maria Calabrese; Rosanna Clima; Piero Pignataro; Vito Alessandro Lasorsa; Michael D Hogarty; Aurora Castellano; Massimo Conte; Gian Paolo Tonini; Achille Iolascon; Giuseppe Gasparre; Mario Capasso Journal: Oncotarget Date: 2016-08-02
Authors: Philipp Rentzsch; Daniela Witten; Gregory M Cooper; Jay Shendure; Martin Kircher Journal: Nucleic Acids Res Date: 2019-01-08 Impact factor: 16.971